Neonatal Long-Chain 3-Ketoacyl-CoA Thiolase deficiency: Clinical-biochemical phenotype, sodium-D,L-3-hydroxybutyrate treatment experience and cardiac evaluation using speckle echocardiography

Annemarijne R.J. Veenvliet a,1, Mark R. Garrelfs a,1, Floris E.A. Udkink ten Cate b, Sacha Ferdinandusse f, Simone Denis f, Sabine A. Fuchs b,e, Marit Schwantje f,h, Rosa Geurtzen c, Annemiek M.J. van Wegberg g, Marleen C.D.G. Huigen d, Leo A.J. Kluitmans d, Ronald J.A. Wanders c,g,h,i, Terry G.J. Derks e, Lonneke de Boer e, Riekelt H. Houtkooper e,f,i, Maaike C. de Vries a,e,2, Clara D.M. van Karnebeek a,c,e,i,j,2

a Radboudumc Amalia Children’s Hospital, Radboud Center for Mitochondrial Medicine, Nijmegen, the Netherlands
b Academic Center for Congenital Heart Disease (ACAHA), Department of Pediatric Cardiology, Amalia Children’s Hospital, Radboud University Medical Center, Nijmegen, the Netherlands
c Amalia Childrens Hospital, department of neonatology, Radboud University Medical Center, Nijmegen, the Netherlands
d Translational Metabolic Laboratory, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands
e United for Metabolic Diseases, the Netherlands
f Laboratory Genetic Metabolic Diseases; Amsterdam Gastroenterology, Endocrinology and Metabolism Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
g Department of Gastroenterology and Hepatology, Dietetics and Intestinal Failure, Radboud University Medical Center, Nijmegen, the Netherlands
h Department of Metabolic Diseases, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, the Netherlands
i Emma Center for Personalized Medicine, Amsterdam UMC, Amsterdam, the Netherlands
j Departments of Pediatrics and Human Genetics, Emma Children’s Hospital, Amsterdam University Medical Centers, Amsterdam, the Netherlands

ABSTRACT

Isolated long-chain 3-keto-acyl CoA thiolase (LCKAT) deficiency is a rare long-chain fatty acid oxidation disorder caused by mutations in HADHB. LCKAT is part of a multi-enzyme complex called the mitochondrial trifunctional protein (MTP) which catalyzes the last three steps in the long-chain fatty acid oxidation. Until now, only three cases of isolated LCKAT deficiency have been described. All patients developed a severe cardiomyopathy and died before the age of 7 weeks. Here, we describe a newborn with isolated LCKAT deficiency, presenting with neonatal-onset cardiomyopathy, rhabdomyolysis, hypoglycemia and lactic acidosis. Bi-allelic 185G>A (p.Arg62His) and c1292T>C (p.Phe431Ser) mutations were found in HADHB. Enzymatic analysis in both lymphocytes and cultured fibroblasts revealed LCKAT deficiency with a normal long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD, also part of MTP) enzyme activity. Clinically, the patient showed recurrent cardiomyopathy, which was monitored by speckle tracking echocardiography. Subsequent treatment with special low-fat formula, low in long chain triglycerides (LCT) and supplemented with medium chain triglycerides (MCT) and ketone body therapy in (sodium-D, L-3-hydroxybutyrate) was well tolerated and resulted in improved carnitine profiles and cardiac function. Resveratrol, a natural polyphenol that has been shown to increase fatty acid oxidation, was also considered as a potential treatment option but showed no in vitro benefits in the patient’s fibroblasts. Even though our patient deceased at the age of 13 months, early diagnosis and prompt initiation of dietary management with addition of sodium-D,L-3-hydroxybutyrate may have contributed to improved cardiac function and a much longer survival when compared to the previously reported cases of isolated LCKAT-deficiency.

ARTICLE INFO

Keywords:
Long-chain 3-keto-acyl CoA thiolase (LCKAT)
Fatty acid oxidation disorder
HADHB
Cardiomyopathy
MTP
Ketones
Resveratrol
Speckle-echocardiography

* Corresponding author at: Department of Pediatrics, Emma Children’s Hospital, Amsterdam University Medical Centers, Location AMC, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.
E-mail address: c.d.vankarnebeek@amsterdamumc.nl (C.D.M. van Karnebeek).
1 Shared first.
2 Shared last.

https://doi.org/10.1016/j.ymgmr.2022.100873
Received 16 April 2022; Accepted 16 April 2022
Available online 4 May 2022
2214-4269/© 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction

Mitochondrial fatty acid β-oxidation (FAO) is an important pathway in the provision of energy. Consequently, energy homeostasis is disrupted in all disorders of fatty acid oxidation (FAODs) [1]. Most FAODs are well-known and responsive to dietary management, wherefore many have been implemented in neonatal screening programs (e.g. Very Long-Chain acyl-CoA Dehydrogenase Deficiency (VLCADD), Medium-Chain acyl-CoA Dehydrogenase Deficiency (MCADD) and Long-Chain 3-Hydroxacyl-CoA Dehydrogenase Deficiency (LCHADD)). Long-Chain 3-Ketoacyl-CoA Thiolase (LCKAT) enzyme function is part of the mitochondrial trifunctional protein (MTP), which harbours two other enzyme activities required for the oxidation of long-chain fatty acids in mitochondria: long-chain enoyl-CoA hydratase (LCEH) and LCHAD. Genetic mutations have been described that affect all three enzymatic activities of MTP (generalized MTP deficiency), which, relative to other FAODs, is less common, appears more severe and seems irresponsible to dietary interventions [1]. Specific mutations can also lead to isolated deficiency of one of the MTP activities, with LCHADD being the most frequent. Isolated LCKAT deficiency is very rare. To date, only three patients have been reported in literature, all with a fatal outcome in the first 7 weeks of life [2,3]. Here we present the fourth case of isolated LCKAT deficiency, define and describe the clinical, biochemical, genetic and cardiac characteristics, as monitored with speckle tracking imaging. Moreover, we share our experience with the in vivo treatment of the patient using a ketone body supplement and in vitro testing of resveratrol as a potential therapy.

Resveratrol is a polyphenol that has protective effects against cardiovascular disease and type 2 diabetes [4]. Though resveratrol has pleiotropic effects, it might increase residual activity of enzymes through activation of sirtuins (deacetylase enzymes) and thereby promoting mitochondrial biogenesis and/or the expression of chaperone proteins that facilitate folding of the defective protein [5]. Moreover, resveratrol increased fatty acid oxidation flux in cells of some patients with VLCADD, especially in patients in whom there is residual VLCAD-activity [6]. We hypothesized that resveratrol might have similar positive effects in fibroblasts of our LCKAT deficient patient.

Furthermore, the effect of ketone body (D,L-3-hydroxybutyrate) supplementation was monitored as a potential dietary strategy, as ketone bodies constitute an alternative energy source when fatty acid or glucose metabolism is impaired. Mounting evidence suggests that the failing heart, irrespective of the cause, is ‘energy starved’ and preferentially relies on ketone bodies as fuel [7–9]. Ketone bodies have been used previously to improve cardiac function in MADD and in glycogen storage disease type III [10–12]. A recent systematic review on 23 MADD patients moreover, showed additional improvement of liver symptoms, muscle symptoms and respiratory failure and longer survival upon ketones than historical controls [13]. Furthermore, in VLCADD patients, ketone esters improved skeletal muscular energy balance and plasma acylcarnitine profiles at least upon exercise [14].

To our knowledge this is the first report of treatment of LCKAT/MTP deficiency with oral ketone bodies, in which cardiac function was used as one of the main outcome measures to guide treatment. Myocardial function was closely monitored using speckle tracking echocardiography, a promising method for early detection of subclinical myocardial dysfunction.

This case report and the comparison to LCKAT deficient patients published before aims to enhance early recognition of this severe condition, delineate the phenotypic spectrum, as well as inform the metabolic community of the potential therapeutic interventions.

2. Materials and methods

2.1. Consent

Written informed consent for publication was obtained from parents. Clinical data were obtained from electronic patient record.

2.2. Metabolic analyses

Standard laboratory analyses (glucose, lactate, blood gasses, ammonia, CK, electrolytes) were performed by the clinical chemistry laboratory in our hospital and local reference values were used. Specialized metabolic analyses were performed in the Translational Metabolic Laboratory at the same hospital. Acylcarnitine profiling in plasma was performed by quantitative electrospray tandem mass spectrometry (ESI/MS-MS) in precursor ion scan mode (m/z 85) essentially as described by Vreken et al. 1999 [15].

In fibroblasts, acylcarnitine profiling was performed after loading the cells with [U-13C] palmitate according to Diekman et al. [16].

LCHAD and LCKAT enzyme activity measurements were performed by the Amsterdam UMC metabolic laboratory and were performed in lymphocytes and fibroblasts using 3-ketopalmitoyl-CoA as substrate at 37 °C, followed by ultra-high performance liquid chromatography to separate the different acyl-CoA species.

Long-chain fatty oxidation (LC-FAO) flux analysis was performed in fibroblasts, as described earlier by measuring the production of radio-labeled H2O from [9,10-3H(N)]-oleic acid [16].

2.3. Genetic analysis

Genetic analysis was performed by Sanger sequencing of all exons and flanking intronic sequences of HADHA and HADHB. Sequence data were compared to the reference sequences NM_000182.4 (HADHA) and NM_000183.2.c.5_7.dup (p.Thr22dup) (HADHB) with nucleotide numbering starting at the first adenine of the translation initiation codon ATG.

2.4. Immunoblot analysis

Immunoblot analysis was performed with fibroblast homogenates from a control subject and the patient. Homogenates were separated on a 10% NuPAGE Bis-Tris gel (Thermo Fisher) in a MOPS buffer and subsequently transferred onto a nitrocellulose membrane, blocked with 4% normal goat serum/PBS/0.1% Tween and probed with polyclonal antibodies raised against rat liver MTP (kind gift from Prof. T. Hashimoto). For visualization the secondary antibody IRDye 800CW goat anti-rabbit was used with the Odyssey Infrared Imaging System (LI-COR Biosciences, Nebraska, USA).

2.5. Cardiac imaging

Conventional echocardiographic investigations were obtained according to the recommendations of the American Society of Echocardiography. In addition, cardiac function at baseline and during follow-up was also assessed by measuring global and segmental longitudinal left ventricular (LV) strain using two-dimensional speckle tracking echocardiography (STE). STE is an advanced echocardiographic technique based on frame by frame tracking of specific greyscaled areas in the myocardial tissue, referred to as speckles, using dedicated commercially available software [17]. It is a validated and feasible method to assess cardiac function in children. Moreover, global longitudinal LV strain is a more sensitive measure of myocardial dysfunction than conventional echocardiographic measures of LV systolic function. STE measures were obtained as previously described elsewhere [17]. In brief, two-dimensional greyscale images from the standard apical views (apical 2-chamber, 4-chamber and long-axis view) were acquired. Analyses were performed offline using dedicated post-processing software (EchoPac 113.0, GE Medical Systems). All echocardiographic measurements were averaged from 3 cardiac cycles [17].

The used software automatically tracked the frame to frame movement of natural acoustic markers, called speckles, during a cardiac cycle.
The LV was automatically divided into 6 myocardial segments, and after analyzing all three standard apical views of the LV, the software displayed the regional peak systolic LV longitudinal strains in an 18-segment model or “bull’s-eye plot” [17], where from inside to outside respectively the apical, mid and basal strain is shown (Fig. 3). Blue and light red color implicates impaired function, where dark red color represents good cardiac function. The average values of the peak systolic LV longitudinal strain were then automatically calculated for each separate apical view and global longitudinal strain of the whole LV.

2.6. Dietary management

Dietary treatment was initiated according to the recommendations for symptomatic patients with a long-chain fatty acid oxidation defects [18]. After diagnosis, our patient was fed with a special low-fat formula, low in LCT and supplemented with MCT (Monogen®) 2.9 g of fat per 100 kcal, of which 16% LCT and 84% MCT.) throughout her life, in combination with frequent feeding. In this article, this diet will be abbreviated as ‘MCT formula’. The emergency regimen consisted out of 1) maltodextrin added to the special MCT formula or 2) a powdered carbohydrate mixture (SOS10®) at 8 mg/kg/min glucose or 3) intravenous glucose-infusion.

2.7. In vitro Resveratrol studies

LC-FAO flux assay was measured in extracts of patient fibroblasts, grown in the presence or absence of 50 μM resveratrol for 24 h at 37 °C. The flux measurements were used to evaluate the resveratrol responsiveness.

2.8. Ketone body therapy with sodium-D-L-hydroxybutyrate

Ketone body therapy was initiated according to the protocol previously described for MADD patients [13]. In the Netherlands, the D,L-3-HB was acquired by Sigma-Aldrich and magisterially prepared as a 593.3 mg/ml (4.7 M) solution in distilled water. Literature on MADD patients described a starting dose of 900 mg/kg/day from the age of 7 months onwards [13]. Our patient was started at 300 mg/kg/day because of a stable clinical condition and low, but measurable plasma ketones before treatment (0.02 mmol/l) and additional treatment with MCT formula as substrate for ketone body synthesis. D,L-3-hydroxybutyrate was administered via a nasale tube. Ketones were checked four times per day (bedside ketone measurements), 1.5 h after administration of sodium D,L-3-hydroxybutyrate. Because hypernatremia and alkalosis were described as biochemical side effects [13], sodium and blood gas analyses were performed regularly.

3. Results

3.1. Case report

The female proband was born at 38 + 5 weeks of gestation after an uncomplicated pregnancy and delivery. There was no history of antenatal deaths and she was born as the first child of healthy, non-consanguineous Caucasian parents. The Apgar scores were 9 and 10, after 1 and 5 min, respectively. Physical examination revealed a low birth weight of 2194 g (−3.4 SD), head circumference of 33 cm (−1.62 SD) and length of 47 cm (−1.83 SD). No congenital malformations were noted. During the first 24 h post-partum the patient developed hypoglycemic episodes which, at that time, were attributed to her low birth weight, which was treated with intravenous glucose for 48 h. Two days after birth the patient became tachypneic, and sepsis work-up revealed an increased C-reactive protein (CRP) level of 21 mg/l (N < 10 mg/l) which rose suspicion of a perinatal infection. Despite treatment with Gentamicin and Penicillin, the patient’s clinical situation deteriorated and cardiopulmonary instability developed. At that time, hypotonia and signs of moderate encephalopathy were observed which cleared up in the following days.

A chest x-ray showed an enlarged heart (Fig. 1) and ECG showed low voltages and repolarization disorders (Fig. 2a). Echocardiography revealed biventricular systolic dysfunction with a left ventricular (LV) shortening fraction of 15% (normal value >29%), biventricular hypertrophy and mild dilatation of the cardiac chambers.

Routine clinical chemistry laboratory tests revealed a severe metabolic acidosis (pH 7.10; HCO3 20 mmol/l CO2 6.3 kPa, BE −11), an increased anion gap (21, N 9-16 mmol/l), elevated lactate levels (8.3 mmol/l; N < 2), hyperammonemia (226 μmol/l; N < 50) and rhabdomyolysis (CK: 10,000 U/l; N < 145). An extensive overview of all clinical chemistry results is given in Table 1.

Due to a combination of circulatory insufficiency and rhabdomyolysis, acute kidney injury (tubular necrosis) occurred with an increase in plasma creatinine levels and oliguria. The patient was mechanically ventilated and required Milrinone for afterload reduction and Noradrenaline to treat hypotension.

Because of the suspicion of an inherited metabolic disorder, protein- and fat intake was stopped and the patient (now 4 days old) was treated with high-dose intravenous glucose infusion (8-10 mg/kg/min) and sodium-benzoate (250 mg/kg/day) to treat the hyperammonemia.

Acylcarnitine analysis in plasma showed normal free carnitine levels, elevated total carnitine and strongly elevated long-chain (hydroxy) acylcarnitine levels (Table 2) on which a mitochondrial trifunctional protein (MTP) deficiency was suspected and the MCT formula was started in combination with a high glucose infusion (8-10 mg/kg/ [19] min) to prevent catabolic situations.

Enzymatic analysis in isolated peripheral blood lymphocytes and in cultured skin fibroblasts revealed an isolated LCKAT deficiency (Table 3). In addition, we measured LC-FAO flux analysis in cultured fibroblasts, which revealed a 16-18% oleate β-oxidation activity compared to controls. Immunoblotting with a homogenate of the patient’s fibroblasts revealed the presence of both the alpha- and beta-subunit of MTP (Fig. 4). The diagnosis of LCKAT deficiency was confirmed by identification of two compound heterozygous pathogenic

Fig. 1. X-thorax.
Fig. 1: X-thorax performed 4 days postpartum which shows an enlarged heart. C represents the maximal span of the heart, T represents the maximal span of the thorax. (Cardial/Thorax ratio (C/T) ratio 0.6 = enlarged).
(class 5) mutations in HADHB (Table 3).

In the following days, the patient recovered clinically and biochemically and ammonia and lactate levels returned to normal. The patient was weaned off of mechanical ventilation and vasopressors were stopped. Milrinone was replaced by an angiotensin-converting enzyme-inhibitor.

The patient was discharged from hospital at the age of one month. The disease course after discharge is shown in Table 4. During the first months after discharge, she was clinically and metabolically stable. At the age of four months, convulsion-like symptoms appeared. Sandifer syndrome was considered as the convolution like symptoms seemed to be mostly related to nutrition, but was later confirmed as epilepsy by electroencephalography. Brain MRI showed no abnormalities. From the age of 4.5 months old, our patient showed mild developmental delay on important milestones. At 5 months she rolled over from back to abdomen for the first time. At 9 months old developmental level was assessed by a physiotherapist using the BSID-III-NL. Fine motor skills were scored normal, however gross motor skills were delayed scoring an overall percentile of 12/100. Delay on gross motor function was mostly based on not being fully able to maintain the abdominal position. Furthermore, she had mild active hypertonia in her legs.

Due to feeding problems, the patient was first partially and eventually completely tube-fed. Complete weaning from tube feeding was tried with a speech therapist, albeit unsuccessful. Maximum fasting time was increased to 5 h at the age of 4 months and to 6 h at the age of 6 months. At the age of 11 months, walnut oil (2 ml/day) was introduced to supplement essential fatty acids, but this was poorly tolerated and discontinued. During her entire lifespan, episodes of reflux, vomiting,

Fig. 2. ECG.
A. Electrocardiogram at presentation showing sinus tachycardia (160 beats per minute (bpm), ref. mean for age 133bmp), low voltages in most leads (i.e. red circle in II, R-voltage in our patient 3 mm, ref. mean for age 6 mm) and negative T-waves in V1 to V6 (red arrows).
B. Electrocardiogram during follow-up at 10 months showing sinusrithm(141bpm, ref. mean for age 160), recovery of the low voltages and negative T-waves. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
The acylcarnitine profile at diagnosis before treatment is presented in the first column (at four days old). Long-chain (hydroxy)carnitines show a reduction in concentration compared to the initial profile upon treatment with the MCT formula and ketone therapy. At 12 months old, an increase of (hydroxylated) C14-C18 is seen, which correlates with the clinical deterioration at that age (see Table 4).

**Table 2: Acylcarnitine profiles.**

| Measurement          | 4 days | 5 days | 6 days | 9 days | 18 days | 26 days | 30 days | 3 months | Ref (µmol/L) |
|----------------------|--------|--------|--------|--------|---------|---------|---------|----------|-------------|
| Free carnitine       | 28.6   | 44.5   | 18.9   | 22.9   | 54.1    | 51.5    | 56.3    | 68.9     | 20-55       |
| C12                  | 1.58   | 0.75   | 0.21   | 0.11   | 0.19    | 0.13    | 0.07    | 0.18     | 0-0.14      |
| C14                  | 2.34   | 1.32   | 0.51   | 0.14   | 0.19    | 0.25    | 0.15    | 0.38      | 0-0.13      |
| C16                  | 6.59   | 3.29   | 1.32   | 0.29   | 0.41    | 0.64    | 0.51    | 1.43      | 0-0.23      |
| C18                  | 0.74   | 0.51   | 0.18   | 0.07   | 0.1     | 0.14    | 0.13    | 0.36      | 0-0.09      |
| C12:1                | 1.16   | 0.4    | 0.11   | 0.03   | 0.04    | 0.06    | 0.03    | 0.13      | 0-0.14      |
| C14:1                | 2.61   | 1.62   | 0.49   | 0.17   | 0.13    | 0.26    | 0.11    | 0.38      | 0-0.17      |
| C14:2                | 0.44   | 0.29   | 0.07   | 0.03   | 0.04    | 0.1     | 0.05    | 0.13      | 0-0.08      |
| C16:1                | 3.49   | 1.72   | 0.76   | 0.17   | 0.19    | 0.25    | 0.18    | 0.52      | 0-0.08      |
| C16:2                | 0.37   | 0.24   | 0.09   | 0.03   | 0.03    | 0.05    | 0.03    | 0.09      | 0-0.21      |
| C18:1                | 4.29   | 2.04   | 0.79   | 0.29   | 0.21    | 0.29    | 0.24    | 0.72      | 0-0.28      |
| C18:2                | 1.79   | 1.31   | 0.44   | 0.2    | 0.17    | 0.26    | 0.19    | 0.46      | 0-0.19      |
| C12-OH               | 0.29   | 0.23   | 0.04   | 0.02   | 0.04    | 0.04    | 0.02    | 0.05      | 0-0.06      |
| C12:1-OH             | 0.16   | 0.14   | 0.03   | 0.01   | 0.02    | 0.02    | 0.01    | 0.03      | 0-0.08      |
| C14-OH               | 0.42   | 0.34   | 0.12   | 0.05   | 0.07    | 0.08    | 0.06    | 0.14      | 0-0.04      |
| C14:1-OH             | 0.32   | 0.23   | 0.07   | 0.03   | 0.03    | 0.04    | 0.02    | 0.07      | 0-0.04      |
| C16-OH               | 2.82   | 1.97   | 0.85   | 0.19   | 0.36    | 0.38    | 0.32    | 0.68      | 0-0.02      |
| C16:1-OH             | 1.34   | 1.03   | 0.39   | 0.11   | 0.13    | 0.16    | 0.12    | 0.3       | 0-0.02      |
| C18-OH               | 0.77   | 0.65   | 0.28   | 0.12   | 0.16    | 0.15    | 0.15    | 0.31      | 0-0.05      |
| C18:1-OH             | 3.42   | 2.45   | 0.8    | 0.25   | 0.23    | 0.27    | 0.21    | 0.52      | 0-0.02      |
proBNP serum levels (Table 4). Importantly, within several weeks after treatment initiation, the apical sparing pattern fully disappeared and the longitudinal strain values recovered (Fig. 3C). At follow-up, further improvement of cardiac function was noted using conventional echocardiography (LV shortening fraction of 31.4% at 3 months) and ECG (Fig. 2b). STE could not be performed in future check-ups due to agitation.

3.3. Treatment

3.3.1. Sodium-D,L-3-hydroxybutyrate treatment

Our patient was started on enteral sodium-D,L-3-hydroxybutyrate (300 mg/kg/day, later increased to 500 mg/kg/day) on day 12 as an additional alternative energy source for the brain, heart and skeletal muscle. Blood ketone body levels were kept between 0.1 and 0.3 mmol/l during treatment. Glucose infusion was gradually reduced and diuretic drugs were given as part of heart failure therapy. The patient was growing well on the MCT formula. Enteral sodium-D,L-3-hydroxybutyrate at a dose 500 mg/kg/day (500 mg/kg/day contains 4.0 mmol/kg sodium [13]) was well-tolerated and no side effects occurred.

Acylcarnitine profiles during treatment showed improvement of the long-chain acylcarnitines C16-18 over time during treatment (Table 2).

3.3.2. LC-FAO flux in the patient’s fibroblasts and the lack of effect of resveratrol

Flux assays were performed before and after the patient’s fibroblasts were exposed to 50 μM of resveratrol. There was no increase in LC-FAO flux in the fibroblasts of the patient after exposure to resveratrol (data not shown).

3.4. Comparison with other LCKAT-cases

A literature search (Pubmed 1987-2021, species: Humans, research type: case-reports, review, systematic review. Search term: Long-Chain 3-Ketoacyl-CoA Thiolase. Result: 67 articles. Screening by author on title and abstract. Result: 2 relevant articles) yielded one case report and one case series describing three unrelated patients (two males and one unreported gender) with isolated LCKAT deficiency (Table 5). LCKAT deficiency was diagnosed by enzymatic (one patient) or genetic (two patients) analysis. All three patients presented in the neonatal period with either an acute metabolic crisis (lactic acidosis, hyperammonemia, hypoglycemia) or with cardiomyopathy, and all died before the age of two months. Causes of death were cardiomyopathy in two patients and metabolic decompensation during an infection in one patient [2,3].
Fig. 4. Western blot.
Western blot for the alpha (HADHA) and beta (HADHB) subunit of the MTP complex in control (C) and patient (P) fibroblasts. Equal amounts of protein (11 μg) were loaded.

4. Discussion

In this case report, we describe a new case of isolated LCKAT deficiency, her early diagnosis, the course of disease, therapeutic considerations and her treatment with D,L-hydroxybutyrate. Due to early diagnosis, a special diet enriched with ketone bodies was initiated, which may have led to the clinical and biochemical improvement and longer survival as observed in our patient when compared to the three previously described cases of isolated LCKAT deficiency [2,3].

LCKAT enzyme is part of MTP, which is a hetero-octamer of four α- and four β-subunits [21], which are encoded by different genes both located on chromosome 2p23 [22]. HADHA encodes the α-subunit which contains LCEH and LCHAD activity, whereas HADHB encodes the β-subunit which contains the LCKAT enzyme. Our patient was compound heterozygous for the c.185G > A (p.Arg62His) and c.1292 T > C (p.Phe431Ser) mutations in HADHB, which have previously been identified in another isolated LCKAT deficient patient (patient 1, Table 5) who died very early in life [2]. Differentiation between LCHAD, LCKAT and MTP deficiency is only possible with enzymatic testing, as was done in our patient. Furthermore, LC-FAO flux-analysis was performed in our patients fibroblasts which showed a clearly reduced LC-FAO flux of 16-18% of control values. LC-FAO flux measurements have shown to predict clinical severity in VLCADD and MADD [24], where LC-FAO fluxes <10% in VLCADD generally correlate with a severe phenotype [16]. The literature on whether LC-FAO flux can be used in predicting disease severity for LCKAT/MTP deficiency is currently very sparse, where only one study on 8 MTP patients and one LCHADD patient showed higher palmitate activity in the fibroblasts of mild phenotypes (50 and 88% n = 2) and lower palmitate activity in severe phenotypes (20-29% n = 4) [25]. No large-scale studies have been performed and to the best of our knowledge, no earlier flux analyses have been performed in cells from patients with isolated LCKAT deficient fibroblasts. Hence, no statements can be made about the correlation between flux analysis and clinical phenotype in our patient.

To date, only three cases of isolated LCKAT deficiency have been reported (Table 5) [2,3]. Deficiencies of the LCHAD enzyme, and the MTP complex in general, have been described more regularly [3,26]. In literature, LCHADD seems to have a more lethal course and a later presentation than MTP-deficiency, as in previous research [26] (n = 21) 50% of the MTP cases presented in the neonatal period with a mean age of presentation of 5.8 monts versus 15% neonatal presentation and a mean age of presentation of 3 months in a study on LCHADD patients [27] (n = 50). The study on MTP-deficient patients revealed a high mortality (76%) mostly caused by cardiomyopathy, whereas the study on LCHADD patients revealed a survival of 62% during a follow-up of 64 months, however with regular metabolic crises (26%). In combination with previously described LCKAT deficient cases and our present case, these findings suggest that isolated LCKAT deficiency leads to an earlier and more severe cardiomyopathic phenotype than LCHADD. The disease course seems to more closely resemble that of general MTP deficiency, but seems to have an even more severe and earlier presentation. Hence, clinical discrimination between general MTP, LCHAD and LCKAT deficiency can be very difficult, if not impossible, because of the overlap in presenting symptoms. Establishing the precise diagnosis is important as prognosis seems to differ between conditions. Because our patient survived longer than the previous described LCKAT-cases, we were able to observe her development which showed delay of gross motor function and development of epilepsy. Neurological problems in MTP-deficient patients were described earlier [28], however involved Charcot-Marie-Tooth-like symptoms which were not applicable to our patient, as no peripheral neuropathy was observed. Epilepsy was described previously in a Korean patient with two novel HADHB mutations which presented on day 5 with lactic acidosis and seizures [29]. This patient eventually passed at the age of 2 months from heart failure. In this patient, it was unclear if the seizures were secondary to his intraparenecymatous frontal bleedings or primary to the HADHB mutations.

4.1. Experiences with Ketones and Resveratrol treatment

The severe disease course in other LCKAT deficient patients with the same mutations motivated us to explore therapeutic strategies. Resveratrol has been found to restore LC-FAO flux in human fibroblasts from patients with Carnitine palmityl transferase 2 (CPT2) and VLCAD deficiencies [30], depending on their mutation type and residual enzyme activity. Indeed, null mutations or large deletions typically precluded resveratrol responsiveness, while a variable response was seen for VLCADD caused by missense mutations. The compound heterozygous missense mutations observed in our LCKAT patient prompted us to test resveratrol responsiveness but, unfortunately, no beneficial effects were found, at least in the patient’s fibroblasts.

General treatment of MTP/LCHAD deficiency usually involves avoidance of prolonged fasting and institution of a carbohydrate-rich, LCT restricted and fat modified diet using MCT supplementation, in our patient given as Monogen. Medium-chain fatty acids may however serve as a substrate to synthesize long-chain fatty acids by chain elongation [31-33] and might therefore be an inadequate source of alternative energy for ATP synthesis and could lead to an unintended increase of toxic long-chain fatty acid metabolites. As alternative therapy, our patient was started on D-L-3-hydroxybutyrate 12 days postpartum and was dosed 4 times daily. Recent pharmacokinetic research on two MADD patients advised a dosing schedule of six to eight times daily upon initiation of D,L-3-hydroxybutyrate, as the concentration of D,L-hydroxybutyrate seemed to return to baseline after 3 hours [34]. Clearly, more research should be done to optimize dosing for LCKAT deficiency and evaluate its effect and safety. Possibly slow release preparations could be beneficial.

To monitor therapy, carnitine profiles were checked regularly (Table 2). Acylcarnitine profiles showed reduction of the elevated long-chain acylcarnitines during treatment, which suggests that β-oxidation was relieved by treatment which is supported by our patients clinical improvement. Previous literature showed one other patient with a FAOD (carnitine-acyl-carnitine translocase deficiency (CACTD)) which was treated neonatally (5 days postpartum) with a MCT formula...
### Table 4

**Disease course.**

|   | T1   | T2   | T3   | T4   | T5     | T6       | T7     |
|---|------|------|------|------|--------|----------|--------|
| Admission respiratory tract infection | No   | No   | No   | Admission metabolic decemination | No     | Admission heart failure | Admission acute heart failure |
| Admission metabolic tract infection | No   | No   | No   | Admission heart failure | No     | Admission acute heart failure | First CK level 212 U/l, after 1 day hospitalization: CK 3371 U/l Lactate 4.9, pH 7.2, CO2 5.4, glucose 6.2 |
| Admission acute heart failure | No   | No   | No   | Admission heart failure | No     | Admission acute heart failure | Sinus tachycardia, negative T-waves in the inferior, lateral and V4-V6 leads |
| First CK level 212 U/l, after 1 day | CK 156 U/l lactate 1.8, pH 7.4, CO2 5.1, glucose 5.3 | CK 7387 U/l lactate 4.7, pH 7.3, CO2 7.3, glucose 4.9 | Not done | CK 20037 U/l lactate 4.0, pH 7.4, CO2 4.5, glucose 7.1 |
| Laboratory investigations | CK 128 U/l | Hydroxybutarate 470 mg/kg/day | Hydroxybutarate 470 mg/kg/day | Hydroxybutarate to 500 mg/kg/day | Hydroxybutarate 500 mg/kg/day |
| Medication | Normal sizes of both ventricles and atria (LVEDD 24 mm; z-score + 0.9); no hypertrophy. | Normal sizes of both ventricles and atria (LVEDD 24 mm; z-score + 0.9); no hypertrophy. | Normal sizes of both ventricles and atria (LVEDD 24 mm; z-score + 0.9); no hypertrophy. | First episode of acute deterioration of cardiac function. Poor systolic LV function (LV FS 18%, normal -29%) and moderate systolic RV function. Dilation of the LV (LVEDD 36 mm; z-score + 3.0). Mild LV hypertrophy. | Not done |
| Echocardiography | Normal sizes of both ventricles and atria (LVEDD 20 mm; z-score + 0.2); no hypertrophy. | Normal sizes of both ventricles and atria (LVEDD 24 mm; z-score + 0.9); no hypertrophy. | Not done | Not done |
| Cardiac | Normal sizes of both ventricles and atria (LVEDD 20 mm; z-score + 0.2); no hypertrophy. | Normal sizes of both ventricles and atria (LVEDD 24 mm; z-score + 0.9); no hypertrophy. | Normal sizes of both ventricles and atria (LVEDD 24 mm; z-score + 0.9); no hypertrophy. | First episode of acute deterioration of cardiac function. Poor systolic LV function (LV FS 18%, normal -29%) and moderate systolic RV function. Dilation of the LV (LVEDD 36 mm; z-score + 3.0). Mild LV hypertrophy. | Not done |
| Laboratory investigations | NT-proBNP 150 pg/ml | NT-proBNP 110 pg/ml | NT-proBNP 190 pg/ml | NT-proBNP 6600 pg/ml | NT pro BNP 6200 pg/ml |
| Medication | Captopril | Hydrochlorothiazide | Spironolactone | Hydrochlorothiazide | Hydrochlorothiazide |
| Development | Laughing, alert, motor functions active, normal reflexes | Stagnation of gross motor skills | Assessment of development: delayed gross motor skills | Normal vision |
| Neurologic | Epilepsy | Convulsion-like symptoms | No convulsions | No convulsions | Recurrence of epilepsy |
| Neurologic | Start levetiracetam | | |
| MRI | MRI at 4 months old: Symmetrical aspect of the myelination pattern, normal for age. No areas of tissue loss. Normal aspect of the basal ganglia. No structural abnormalities demonstrated |
| Gastrointestinal | Partly drinking, partly tube feeding | Limited to tube feeding | Vomiting | Laparoscopic gastrostomy, obstruction and gagging | Obstruction |
| Reflux: start Nexam | Exclusively Monogen© (16.8 g/100 ml) - 96 kcal/kg | - 129 ml/kg | - 6 feeds per day | Emergency regime during admission: Monogen (17 g/100 ml) + 5 g maltodextrine per bottle. | Emergency regime during admission: iv glucose 10% 8 mg/kg/min |
| Diet | Maximal fasting: 4 h Extension to 5 h during the night. | Maximum fasting: 4 h Maximum fasting: 4 h Maximum fasting: 4 h | Maximum fasting: 4 h Extension to 5 h during the night. | Maximum fasting: 4 h Extension to 5 h during the night. | Maximum fasting: 4 h Extension to 5 h during the night. |
| | Maximum fasting: 4 h Extension to 5 h during the night. | Maximum fasting: 4 h Extension to 5 h during the night. | Maximum fasting: 4 h Extension to 5 h during the night. | Maximum fasting: 4 h Extension to 5 h during the night. | Maximum fasting: 4 h Extension to 5 h during the night. |

**Notes:**
- **Medication:**
  - Captopril
  - Hydrochlorothiazide
  - Spironolactone
  - Furosemide
- **Development:**
  - Laughing, alert, motor functions active, normal reflexes
- **Neurologic:**
  - Epilepsy: No convulsions
- **Gastrointestinal:**
  - Reflux: start Nexam
  - Exclusively Monogen© (16.8 g/100 ml)
  - - 99 kcal/kg
  - - 134 ml/kg
  - - 8 feeds per day
- **Diet:**
  - Maximum fasting: 4 h Extension to 5 h during the night.
  - Maximum fasting: 4 h Extension to 5 h during the night.
  - Maximum fasting: 4 h Extension to 5 h during the night.

**Laboratory investigations:**
- NT-proBNP 150 pg/ml
- NT-proBNP 110 pg/ml
- NT-proBNP 190 pg/ml
- NT-proBNP 6600 pg/ml
- NT pro BNP 6200 pg/ml
- NT pro-BNP 9700 pg/ml

**Medication:**
- Captopril
- Hydrochlorothiazide
- Spironolactone
- Furosemide

**Development:**
- Laughing, alert, motor functions active, normal reflexes

**Neurologic:**
- Epilepsy: No convulsions

**Gastrointestinal:**
- Reflux: start Nexam
- Exclusively Monogen© (16.8 g/100 ml)
- - 99 kcal/kg
- - 134 ml/kg
- - 8 feeds per day

**Diet:**
- Maximum fasting: 4 h Extension to 5 h during the night.
- Maximum fasting: 4 h Extension to 5 h during the night.
- Maximum fasting: 4 h Extension to 5 h during the night.

**Notes:**
- **Medication:**
  - Captopril
  - Hydrochlorothiazide
  - Spironolactone
  - Furosemide
- **Development:**
  - Laughing, alert, motor functions active, normal reflexes
- **Neurologic:**
  - Epilepsy: No convulsions
- **Gastrointestinal:**
  - Reflux: start Nexam
  - Exclusively Monogen© (16.8 g/100 ml)
  - - 99 kcal/kg
  - - 134 ml/kg
  - - 8 feeds per day
- **Diet:**
  - Maximum fasting: 4 h Extension to 5 h during the night.
  - Maximum fasting: 4 h Extension to 5 h during the night.
  - Maximum fasting: 4 h Extension to 5 h during the night.
supplemented with sodium-D,L-3-hydroxybutyrate, which resulted in clinical improvement and increased cardiac function within 4 days of treatment, endorsing the possible importance of initiating this ketone-body in very early stage of disease [35].

4.2. Cardiac evaluation

Myocardial impairment resulting in cardiomyopathy and heart failure is commonly encountered in long-chain fatty acid oxidation disorders [36]. This report highlights the adjunctive role of STE in metabolic disorders with multiorgan involvement. Our patient presented with a cardiomyopathy in the neonatal period. Energy depletion and accumulation of toxic metabolic products are thought to play a major pathophysiologic role in the development of myocardial disease [36–39]. Although typical characteristics of cardiomyopathy were easily recognized using conventional echocardiography in our patient, STE identified important additional echocardiographic features, which may increase our understanding of the mechanisms contributing to the development of myocardial disease in long-chain fatty acid oxidation disorders. Furthermore, we used the strain data obtained with STE to monitor cardiac function in our patient during treatment initiation, and to make adjustments in the maintenance treatment.

An interesting finding in this report, is that we encountered an apical sparing pattern of longitudinal strain (LS) in our patient. Apical sparing is a pattern of regional (segmental) differences in longitudinal strain in which LS in the basal and midventricular segments of the LV is more severely impaired compared with the strain values in the apical segments [20]. Although a reduction in the global longitudinal strain of the LV is a common finding in any myocardial disease associated with impaired systolic ventricular function, apical sparing, is highly specific for infiltrative cardiomyopathies caused by systemic oxalosis and cardiac amyloidosis [40,41]. Moreover, apical sparing in these diseases seems associated with more severe myocardial disease and worse clinical prognosis [40,41]. To the best of our knowledge, we report the first case of apical sparing in an infant with a metabolic condition. We also showed that this abnormal pattern of strain vanished after initial successful treatment of the metabolic derangements associated with this disease, suggesting that the cardiomyopathy seems (partially) reversible and could be a reason to optimize therapy. Previous studies have suggested that apical sparing in cardiac oxalosis and amyloidosis might be explained by regional differences in the distribution of oxalate or amyloid deposits, respectively, with lesser deposits at the apical segments [40,41]. It seems likely that other mechanisms, such as the preferential involvement of specific myocardial fiber subtypes or a higher degree of remodeling, damage or inflammation at the base and midventricular segments, may be involved as well in the pathophysiological basis of apical sparing [40,41]. In line with this hypothesis, a potential pathophysiologic mechanism of apical sparing in LKCAT deficiency may be the heterogeneous myocardial energy disturbance, cardiac damage, tissue remodeling and the accumulation of toxic substances in the myocardium. Because the apical sparing pattern was reversible within a relatively short period of time following treatment initiation, we suggest that acute accumulation of toxic metabolites may play a significant role in myocardial dysfunction in LKCAT deficiency, followed by chronic myocardial remodeling and progression of myocardial dysfunction due to ongoing tissue damage. The echocardiographic findings in our report, however, do not allow for a direct mechanistic explanation, nor does it provide evidence as to why the basal and midventricular LV segments are disproportionately more involved relative to the apex in our patient. Whether apical sparing is a feature of more severe disease in long-chain fatty acid disorders as well remains to be determined.

5. Conclusion

Isolated LKCAT deficiency is a rare long-chain fatty acid oxidation disorder. In this paper we describe the fourth patient, who presented...
neonatally and was treated experimentally with a carbohydrate-rich, long-chain fatty acid oxidation disorder isolated LCKAT deficiency, de
scribed our experience with ketone therapy and defines cardiac evalu
ification using speckle echocardiography.

### 6. Future perspectives

Deep phenotyping of more isolated LCKAT deficient patients will help further elucidate the disease course, both clinically and biochemically. To evaluate therapeutic interventions the N-of-1 study design (on-off, blinded and placebo controlled) might prove useful, as meta-analysis of such individual trials generated evidence level 1 [42]. Both clinical, biochemical and patient reported outcomes should be identified. Furthermore, pharmaco kinetic and -dynamic studies should be done to identify safe and effective dosing. Such efforts will hopefully result in patient survival for this rare yet debilitating disease.

### Synopsis

This article provides new insight into the disease course of the rare long-chain fatty acid oxidation disorder isolated LCKAT deficiency, describes our experience with ketone therapy and defines cardiac evaluation using speckle echocardiography.

### Table 5: An overview of the three isolated LCKAT deficient cases described in literature. Case 1 [2] is an LCKAT deficient patient with the same genotype as our patient. For case 2 [3], enzyme activity or Western Blot was not provided. Case 3 [3] was described earlier as a LCKAT-deficient patient. Enzyme activity was not specified, Western Blot was not provided. *N.D.: not done.

| Case | Ethnicity | Pregnancy/birth complications | Delivery | Weeks gestation | Birth weight | Mutations | Enzyme activities (nmol/min/mg protein) | Symptoms | Treatment | Deceased | Cause of death |
|------|-----------|--------------------------------|----------|----------------|-------------|-----------|--------------------------------------|----------|-----------|----------|---------------|
| 1    | Caucasian | Healthy                        | C-section| 35 weeks       | 1900 g/3rd percentile | c.185 G > A (p.Arg62His); c.1292 T > C (p.Phe431Ser) | LCKAT 0.8 (ref 20); Enzymatic deficiency, not specified | Cardiomyopathy, Transient Hypotonia, Cardiomyopathy | Glucose | Yes, age: 6 weeks | Yes: age 6 weeks |
| 2    | Caucasian | Placenta insufficiency         | C-section| 35 weeks       | 1900 g/3rd percentile | c.185 G > A (p.Arg62His); c.1202 T > G (protein change not reported) | LCKAT 0.8 (ref 20); Enzymatic deficiency, not specified | Lactic acidosis, Hypotonia, Cardiomyopathy | MCT formula | Yes: age 7 weeks | Yes: age 7 weeks |
| 3    | Caucasian | HELLP syndrome                 | C-section| 36 weeks       | 2460/25th percentile | Mutation not identified | LCKAT 0.8 (ref 20); Enzymatic deficiency, not specified | Metabolic acidosis, Hyperammonia, Hyperlactacidosis, Tachypnea, Hypothermia | Glucose | Yes: age 8 days | Yes: age 8 months |

### Author contribution statement

Annemarijne R.J. Veenvliet and Mark R. Garrelfs performed data acquisition, designed the tables and figures, and drafted the article. Floris Udink ten Cate performed data acquisition, supplied figures and contributed to drafting the article. Sabine Fuchs, Marit Schwantje are members of the national expertise center for long chain fatty acid oxidation disorders and provide clinical care for the national pediatric patients with these diseases. They helped shape the clinical context and reviewed and edited the manuscript. Ronald J.A. Wanders was involved with the biochemical and especially enzymological characterization of the patient and reviewed and edited the manuscript. Rosa Geurtzen performed data acquisition and reviewed and edited the manuscript. Anneliese M.J. van Wegberg performed data acquisition and contributed to drafting the article. Sacha Ferdinandusse, Simone Denis, Marleen C.D.G. Huijen, Leo A.J. Kluftmans and Riekelt H. Houtkooper, performed and supervised the measurements/experiments and reviewed and edited the manuscript. Terry Derks and Lonneke de Boer performed data acquisition and reviewed and edited the manuscript. Maaik C. de Vries and Clara D.M van Karnebeek designed the study, supervised the project and manuscript writing. All authors approved the final version of the manuscript.

### Funding

This research received funding from the not-for-profit sector: Stichting Metakids NL salary award to CvK. This research did not receive any specific grant from funding agencies in the public or commercial sectors.
Patient consent statement

Yes.

Declaration of Competing Interest

We have no conflicts of interest to report.

Acknowledgements

We acknowledge Derk P. Allersma, PhD, hospital pharmacist at the Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands for the swift preparation and distribution of magisterially prepared sodium-D,L-3-hydroxybutyrate.

References

[1] S.J. Knottnerus, et al., Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle, Rev. Endocr. Metab. Disord. 19 (1) (2018) 93–106.
[2] A.M. Das, et al., Isolated mitochondrial long-chain ketocar-CoA thiolase deficiency resulting from mutations in the HADHB gene, Clin. Chem. 52 (3) (2006) 530–534.
[3] J. Sander, et al., Neonatal screening for defects of the mitochondrial trifunctional protein, Mol. Genet. Metab. 85 (2) (2005) 108–114.
[4] J.A. Baur, D.A. Sinclair, Therapeutic potential of resveratrol: the in vivo evidence, Nat. Rev. Drug Discov. 5 (6) (2006) 493–506.
[5] J.C. Bleeker, R.H. Houkko, Sirtuin activation as a therapeutic approach against inborn errors of metabolism, J. Inherit. Metab. Dis. 39 (4) (2016) 565–572.
[6] J. Bastin, F. Djouadi, Resveratrol and myopathy, Nutrients 8 (5) (2016) 254.
[7] G. Aubert, et al., The failing heart relies on ketone bodies as a fuel, Circulation 133 (8) (2016) 698–705.
[8] G. Voros, et al., Increased cardiac uptake of ketone bodies and free fatty acids in human heart failure and hypertrophic left ventricular remodeling, Circ. Heart Fail. 11 (12) (2018), e004953.
[9] L.C. Gormsen, et al., Ketone body infusion with 3-hydroxybutyrate reduces myocardial glucose uptake and increases blood flow in humans: a positron emission tomography study, J. Am. Heart Assoc. 6 (3) (2017), e005066.
[10] J.L. Van Hove, et al., D, L-3-hydroxybutyrate treatment of multiple acyl-CoA dehydrogenase deficiency (MADD), Lancet 361 (9367) (2003) 1433–1435.
[11] T. Fischer, et al., Ketone body therapy with D/L-3-hydroxybutyric acid solution in severe MADD, Mol. Genet. Metabol. Rep. 20 (2019), 100491.
[12] V. Vaylavanopoulos, et al., Successful treatment of severe cardiomyopathy in glycogen storage disease type III with D, L-3-hydroxybutyrate, ketogenic and high-protein diet, Pediatr. Res. 70 (6) (2011) 638–641.
[13] W.J. van Rijt, et al., Efficacy and safety of D, L-3-hydroxybutyrate (D, L-3-HB) treatment in multiple acyl-CoA dehydrogenase deficiency, Genet. Med. 22 (5) (2020) 908–916.
[14] J.C. Bleeker, et al., Nutritional ketosis improves exercise metabolism in patients with very long-chain acyl-CoA dehydrogenase deficiency, J. Inherit. Metab. Dis. 43 (4) (2020) 787–799.
[15] P. Verken, et al., Rapid diagnosis of organic acidemias and fatty-acid oxidation defects by quantitative electrospray tandem-MS acyl-carnitine analysis in plasma, in: Current Views of Fatty Acid Oxidation and Ketogenesis, Springer, 2002, pp. 327–337.
[16] E.F. Diekman, et al., Fatty acid oxidation flux predicts the clinical severity of VLCAD deficiency, Genet. Med. 17 (12) (2015) 989–994.
[17] R. Lagies, et al., Subclinical myocardial disease in patients with primary hyperoxaluria and preserved left ventricular ejection fraction: a two-dimensional speckle-tracking imaging study, Pediatr. Nephrol. 34 (12) (2019) 2591–2600.
[18] U. Spierkerkoetter, et al., Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop, J. Inherit. Metab. Dis.: Off. J. Soc. Study Inborn Errors Metabol. 32 (4) (2009) 498–505.
[19] J. Vockley, et al., Results from a 78-week, single-arm, open-label phase 2 study to evaluate UX007 in pediatric and adult patients with severe long-chain fatty acid oxidation disorders (LC-FAOD), J. Inherit. Metab. Dis. 42 (1) (2019) 169–177.
[20] R. Lagies, et al., Apical Sparing of Longitudinal Strain, Left Ventricular Rotational Abnormalities, and Short-Axis Dysfunction in Primary Hyperoxaluria Type 1, Circ. Heart Fail. 6 (4) (2013) e45–e47.
[21] S. Ushikubo, et al., Molecular characterization of mitochondrial trifunctional protein deficiency: formation of the enzyme complex is important for stabilization of both alpha-and beta-subunits, Am. J. Hum. Genet. 58 (5) (1996) 979.
[22] B.-Z. Yang, et al., The genes for the α and β subunits of the mitochondrial trifunctional protein are both located in the same region of human chromosome 2p23, Genomics 37 (1) (1996) 141–143.
[23] I. Diebold, et al., HADHA and HADHB gene associated phenotypes-identification of rare variants in a patient cohort by next generation sequencing, Mol. Cell. Probes 44 (2019) 14–20.
[24] W.J. van Rijt, et al., Prediction of disease severity in multiple acyl-CoA dehydrogenase deficiency: A retrospective and laboratory cohort study, J. Inherit. Metab. Dis. 42 (5) (2019) 876–889.
[25] S. Olpin, et al., Biochemical, clinical and molecular findings in LCHAD and general mitochondrial trifunctional protein deficiency, J. Inherit. Metab. Dis. 28 (4) (2005) 533–544.
[26] M.E. den Boer, et al., Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: clinical presentation and follow-up of 50 patients, Pediatrics 109 (1) (2002) 99–104.
[27] M.E. den Boer, et al., Mitochondrial trifunctional protein deficiency: a severe fatty acid oxidation disorder with cardiac and neurologic involvement, J. Pediatr. 142 (6) (2003) 684–689.
[28] R. Dagher, R. Massie, B.J. Gentil, MTP deficiency caused by HADHB mutations: Pathophysiology and clinical manifestations, Mol. Genet. Metab. 133 (1) (2021) 1–7.
[29] H.-D. Park, et al., Two novel HADHB gene mutations in a Korean patient with mitochondrial trifunctional protein deficiency, Ann. Clin. Lab. Sci. 39 (4) (2009) 399–404.
[30] J. Bastin, A. Lopes-Costa, F. Djouadi, Exposure to resveratrol triggers pharmacological correction of fatty acid utilization in human fatty acid oxidation-deficient fibroblasts, Hum. Mol. Genet. 20 (10) (2011) 2048–2057.
[31] S. Tuceri, S. Behringer, U. Spierkerkoetter, De novo fatty acid biosynthesis and elongation in very long-chain acyl-CoA dehydrogenase-deficient mice supplemented with odd or even medium-chain fatty acids, FEBS J. 282 (21) (2015) 4242–4253.
[32] P.M. Jones, et al., Medium-chain fatty acids undergo elongation before β-oxidation in fibroblasts, Biochem. Biophys. Res. Commun. 346 (1) (2006) 193–197.
[33] S.J. Knottnerus, et al., Exploring the metabolic fate of medium-chain triglycerides in healthy individuals using a stable isotope tracer, Clin. Nutr. 40 (3) (2021) 1396–1404.
[34] W.J. van Rijt, et al., Enantiomer-specific pharmacokinetics of D, L-3-hydroxybutyrate: Implications for the treatment of multiple acyl-CoA dehydrogenase deficiency, J. Inherit. Metab. Dis. 44 (4) (2021) 926–938.
[35] K. Bhattacharya, et al., The use of sodium DL-3-Hydroxybutyrate in severe acute neuro-metabolic compromise in patients with inherited ketone body synthetic disorders, Orphan. J. Rare Dis. 15 (1) (2020) 1–9.
[36] N.A. Oey, et al., Long-chain fatty acid oxidation during early human development, Pediatr. Res. 57 (6) (2005) 755–759.
[37] J.J. Lehman, D.P. Kelly, Transcriptional activation of energy metabolic switches in the developing and hypertrophied heart, Clin. Exp. Pharmacol. Physiol. 29 (4) (2002) 359–365.
[38] U. Spierkerkoetter, et al., Intrauterine cardiomyopathy and cardiac mitochondrial proliferation in mitochondrial trifunctional protein (TFP) deficiency, Mol. Genet. Metab. 94 (4) (2008) 428–430.
[39] C. Burste, et al., Mitochondrial trifunctional protein deficiency: severe cardiomyopathy and cardiac transplantation, in: JIMD Reports Vol. 40, Springer, 2017, pp. 91–95.
[40] D. Phelan, et al., Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis, Heart 98 (10) (2012) 1442–1448.
[41] A. Senapati, et al., Prognostic implication of relative regional strain ratio in cardiac amyloidosis, Heart 102 (10) (2016) 748–754.
[42] A.R. Müller, et al., Systematic review of N-of-1 studies in rare genetic neurodevelopmental disorders: the power of 1, Neurology 96 (11) (2021) 529–540.